Eli Lilly and Co.the manufacturer of Zepbound and Mounjaro, announced the success of his clinical trial of phase 3 for a GLP-1 pill once a day: an oral form of the box office medication used for diabetes and weight loss.
The drug trial, Orforglpron, measured its efficacy and safety in adults with type 2 diabetes compared to a placebo. He found that the pill decreased A1c, a blood level used to diagnose diabetes, at an average of 1.3% to 1.6%, in different doses, after 40 weeks.
Participants who took the highest dose also lost an average of 16 pounds.
“Since participants had not yet reached a weight plateau at the time the study was completed, it seems that the weight was not yet reached,” the company said in a statement. He did not include information on the demographics of the people who participated in the trial.
The most commonly reported adverse effects were mild to moderate gastrointestinal problems, such as diarrhea, nausea, indigestion, constipation and vomiting.
The pill, which would offer an alternative to injections, is the first oral GLP-1 of small molecules to succeed in a phase 3 rehearsal, said the company.
Eli Lilly claims that he plans to submit Perforglprgron to the United States Food and Drug Administration for approval as a treatment of type 2 diabetes in 2026. For weight management, he plans to send the drug to world regulatory agencies at the end of this year.
“If it is approved, the company is confident in its ability to launch Orforglpronpron worldwide without supply restrictions,” the statement said. “This would be Lilly’s mission to reduce chronic diseases such as type 2 diabetes, which is expected to affect a dear of 760 million adults by 2050.”